TICKERNERD
Menu
QUREQUREHealthcare · Biotechnology

QURE Stock Forecast: UniQure NV Price Predictions for 2026-2027

Last close, 11 Sept 2026
$45
+0.09% on the day

The 13 Wall Street analysts covering UniQure NV hold a median 12-month price target of $70 — +56.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$3.1B
Ticker Nerd rank
57 / 100
Median analyst target
$70
Analysts covering
13
Revenue$5.8M+11.0% y/y
Operating income−$44.7M
Net income−$81.1M
Free cash flow−$29.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.8%
1M
−1.1%
YTD
+86.0%
1Y
+162.8%
From 52W high
−36.9%
From 52W low
+392.9%
$9
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QURE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores UniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Momentum
85
Value
67
Accruals
65
Growth
54
Revisions
45
Volatility
40
Size
30
Issuance
16

Quality (88): The business earns solid, repeatable profits on what it owns.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QURE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26QUREHigh $95Median $70Low $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $47Median $70High $95

The green dot is the last close — the median target sits +56.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
2 Sept 2026William BlairReinstatesOutperform—
30 July 2026BarclaysMaintainsOverweight$65 → $60
30 July 2026BarclaysMaintainsOverweight—
30 July 2026Wells FargoMaintainsOverweight$60 → $75
30 July 2026Wells FargoMaintainsOverweight—
30 July 2026Wolfe ResearchUpgradeOutperform—
30 July 2026Wolfe ResearchUpgradeOutperform$65
29 June 2026HC Wainwright & Co.MaintainsBuy$50 → $80
29 June 2026HC Wainwright & Co.MaintainsBuy—
25 June 2026MizuhoMaintainsOutperform—
25 June 2026MizuhoMaintainsOutperform$35 → $68
18 June 2026BarclaysUpgradeOverweight—
18 June 2026Goldman SachsMaintainsNeutral—
18 June 2026Leerink PartnersMaintainsOutperform—
18 June 2026RBC CapitalMaintainsOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
30 Apr 2026Chardan CapitalMaintainsBuy—
20 Apr 2026Goldman SachsMaintainsNeutral—
23 Mar 2026BarclaysMaintainsEqual-Weight—
11 Mar 2026MizuhoUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QURE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QURE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, UniQure NV returned +162.8% against +17.5% for the S&P 500, dividends included.

QURE vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400Oct 25Jan 26Apr 26Jul 26QURES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QURE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
8
Fundamentals

UniQure NV (QURE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.9×

Cheaper than 94% of US stocks

Price / sales
165.4×

Cheaper than 3% of US stocks

Price / book
9.5×

Cheaper than 10% of US stocks

EV / EBITDA
−15.5×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
11.0%

Higher than 55% of US stocks

Earnings growth (YoY)
11.0%

Higher than 49% of US stocks

Gross margin
94.0%

Higher than 98% of US stocks

Operating margin
−872.2%

Higher than 6% of US stocks

Net margin
89.5%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−157.6%

Higher than 9% of US stocks

Return on assets
−15.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

UniQure NV (QURE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • UniQure NV has a market value of $3.1B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $18.7M. The latest quarter grew 11.0% year on year.

  • Net income over the same four quarters: −$252.2M, a −1350.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$161.5M.

  • Shares outstanding: 69.3M.

  • Trailing P/E: −12.9×; forward P/E: −14.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • UniQure NV employs 221 people — $84K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

QURE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QUREUniQure NV$3.1B
57
CLDXCelldex Therapeutics, Inc.$2.9B
30
ARQTArcutis Biotherapeutics, Inc.$2.9B
88
MBXMBX Biosciences, Inc.$2.9B
38
RCUSArcus Biosciences, Inc.$3.2B
59
IRONDisc Medicine, Inc.$2.8B
38
IMNMImmunome, Inc.$2.8B
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own UniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QURE news & analysis

QURE Submits Application for Gene Therapy for Huntington's Disease

Zacks Investment Research · 3 Sept 2026positive

UniQure NV (QURE) has submitted an application seeking accelerated FDA approval for its gene therapy AMT-130 for Huntington's disease. The company is also pursuing Priority Review and a regulatory filing in the U.K., adding momentum to its regulatory efforts.

Why it matters — A QURE watcher would care because the regulatory submissions for AMT-130 represent a significant step forward in the pipeline for this gene therapy candidate.

15 Stocks to Watch With Short Squeeze Potential

Schaeffers Research · 2 Sept 2026neutral

Schaeffers Research published a list of 15 stocks with short squeeze potential, including UniQure (QURE), while noting that rising bond yields have put the broader market on edge and that short squeezes warrant attention from contrarian traders.

Why it matters — A QURE watcher would care because being flagged on a short-squeeze watchlist points to elevated short interest, which can drive notable trading activity in the stock.

uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

Benzinga · 2 Sept 2026positive

uniQure submitted a Biologics License Application to the FDA seeking accelerated approval for AMT-130, its investigational gene therapy for Huntington's disease. The application was filed on Wednesday, and the submission is viewed as a potential catalyst pending FDA acceptance.

Why it matters — FDA acceptance of the application would move AMT-130 closer to potential market approval, a significant regulatory milestone for uniQure's lead Huntington's program.

UniQure's Embattled Huntington's Gene Therapy Clears A Key Hurdle

Investors Business Daily · 2 Sept 2026neutral

The FDA accepted UniQure's application for approval of its Huntington's disease gene therapy, clearing a key regulatory hurdle. UniQure stock wavered following the announcement.

Why it matters — A QURE watcher would care because FDA acceptance of the application is a significant step toward a potential approval decision for the company's Huntington's gene therapy.

uniQure seeks US approval for Huntington's gene therapy after FDA reversal

Reuters · 2 Sept 2026positive

uniQure said it has applied for U.S. approval of its experimental Huntington's disease gene therapy after the FDA reversed its earlier position on the drug. Shares rose 5% in premarket trading following the announcement.

Why it matters — A U.S. approval application for its lead Huntington's therapy represents a significant regulatory milestone for uniQure, and the FDA's reversal improves the drug's path to market.

FAQ

Frequently asked questions about QURE stock

What is the QURE stock price forecast for 2026-2027?

The 13 Wall Street analysts covering UniQure NV have a median 12-month price target of $70, with estimates ranging from $47 to $95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QURE stock a buy right now?

Of the 13 analysts covering UniQure NV, 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UniQure NV 57 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QURE?

As at 10 Sept 2026, UniQure NV ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will QURE stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +56.6% from the last close, and Ticker Nerd's factor model ranks UniQure NV 57 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QURE stock forecast for 2030?

No analyst covering UniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $95 over the next 12 months.

How has QURE stock performed over the past year?

UniQure NV returned +162.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does UniQure NV do?

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases.

What is the latest news on QURE?

The most recent item we track (Zacks Investment Research, 3 Sept 2026): "QURE Submits Application for Gene Therapy for Huntington's Disease". UniQure NV (QURE) has submitted an application seeking accelerated FDA approval for its gene therapy AMT-130 for Huntington's disease. The company is also pursuing Priority Review and a regulatory filing in the U.K., adding momentum to its regulatory efforts.

Company

About UniQure NV.

uniQure N.V. is a biopharmaceutical company focused on gene therapy for patients with severe genetic and other serious diseases. Its current portfolio includes HEMGENIX for hemophilia B and a pipeline of investigational therapies aimed at disorders such as Huntington’s disease, epilepsy, ALS, and Fabry disease. The company uses an adeno-associated virus (AAV) platform to develop one-time treatments designed to address the underlying cause of disease, with activities spanning research, development, manufacturing, and commercialization. Headquartered in Amsterdam, the Netherlands, uniQure serves the rare-disease and specialty therapeutic markets through both proprietary programs and selected partnerships.

CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com